Zelenetz AD et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a Phase 3 randomized double-blind placebo-controlled study. Proc ASH 2015;Abstract LBA-5.

Lampson BL et al. Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities. Proc ASH 2015;Abstract 497.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.